History and progress of CD38 in myeloma

Maintenance therapy in young myeloma patients beneficial after autologous stem cell transplant

History of antiangiogenic drugs in multiple myeloma, starting with thalidomide

Elderly patients should be treated based on biological age, not chronological

Cancer or amyloidosis?

Monoclonal antibodies in multiple myeloma

Preemptively treating patients most at risk of progression to myeloma

Drug combos with daratumumab likely to become standard of care in myeloma

Overview of the CD38 antibody in multiple myeloma

New drugs and combinations in haematological cancers improve complete remission rates

Benefits and problems of allogeneic stem cell transplantation as multiple myeloma treatment

Coming of age for CDK 4/6 inhibitors: Welcome and interactive session